Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
4
67%
Ph not_applicable
1
17%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Terminated(2)

Detailed Status

Withdrawn2
Active, not recruiting2
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
N/A1 (16.7%)

Trials by Status

withdrawn233%
recruiting117%
active_not_recruiting233%
completed117%

Recent Activity

3 active trials
Showing 5 of 6
completedphase_2

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

NCT03199274
active_not_recruitingnot_applicable

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

NCT03896646
recruitingphase_1

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

NCT06058663
active_not_recruitingphase_2

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NCT03457948
withdrawnphase_2

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

NCT05315687
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03199274Phase 2

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Completed
NCT03896646Not Applicable

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Active Not Recruiting
NCT06058663Phase 1

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
NCT03457948Phase 2

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Active Not Recruiting
NCT05315687Phase 2

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Withdrawn
NCT05157451Phase 2

Y-90 Versus SBRT for Inoperable HCC

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6